Apigenin exerts protective effect and restores ovarian function in dehydroepiandrosterone induced polycystic ovary syndrome rats: a biochemical and histological analysis
Polycystic ovarian syndrome (PCOS) is one of the major causes encouraging the elevation of androgens, obesity along with menstrual complications. Here we study the effect of Apigenin in rat model of polycystic ovarian syndrome. Female Sprague Dawley (SD) rats were treated with Dehydroepiandrosterone...
Gespeichert in:
| Veröffentlicht in: | Annals of medicine (Helsinki) 2022-12, Vol.54 (1), p.578-587 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 587 |
|---|---|
| container_issue | 1 |
| container_start_page | 578 |
| container_title | Annals of medicine (Helsinki) |
| container_volume | 54 |
| creator | Peng, Fangxin Hu, Yichuan Peng, Shu Zeng, Ni Shi, Lei |
| description | Polycystic ovarian syndrome (PCOS) is one of the major causes encouraging the elevation of androgens, obesity along with menstrual complications. Here we study the effect of Apigenin in rat model of polycystic ovarian syndrome.
Female Sprague Dawley (SD) rats were treated with Dehydroepiandrosterone (DHEA) (6 mg/100g) opting the post-pubertal approach for developing rat model of polycystic ovarian syndrome, Metformin was used as standard. The treatments were given for 21 days along with coloproctological analysis. After the treatment regimen, the biochemical analysis was carried in plasma samples, whereas the ovaries were submitted for histopathological analysis.
The treatment of DHEA resulted in disturbed lipid profile and anti-oxidant status along with increased weight, ovarian diameter and cysts in rats confirming the development of PCOS. However, treatment of Apigenin showed ameliorative effect by improving the lipid profile and anti-oxidant status, the treatment also normalised the body weight, reduced ovarian diameter, cysts and restored the healthy follicles compared to control rats. The treatment of Apigenin also suppressed the levels of oestradiol and testosterone compared to control group, also, levels of progesterone were increased in Apigenin treated group of rats. The treatment of Apigenin suppressed the levels of inflammatory cytokines TNF-α and IL-6. It was observed that the effect of Apigenin were to some extent parallel to standard drug Metformin.
The findings confirmed that Apigenin ameliorates the disturbed hormonal levels, lipid profile and antioxidant status in PCOS rats. |
| doi_str_mv | 10.1080/07853890.2022.2034933 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_07853890_2022_2034933</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_20d781b5cfaa48198821cc6e6d8d8918</doaj_id><sourcerecordid>2628683178</sourcerecordid><originalsourceid>FETCH-LOGICAL-c534t-ceebd0ca4ab9eb6f67917b245d3ab01782f2d14218495f52f6518740fadee5133</originalsourceid><addsrcrecordid>eNp9Ustu1TAQjRCIlsIngLxkc4sfceKwQFQVj0qV2MDamtjje10ldrBzL-ST-Et8H63oho3HmjlzzozmVNVrRi8ZVfQdbZUUqqOXnHJeHlF3Qjypzplo5IrThj6tzveY1R50Vr3I-Y5SyltGn1dnQjLJFaXn1Z-rya8x-EDwN6Y5kynFGc3sd0jQufIjECxJmOdYHhJ3kDwE4rahgGIgpdPiZrEp4lQKJeYZUwxYKnZr0JIpDotZ8uzNoXshednDRiQJ5vyeAOl9NBscvYHhoLbxRW2I61MChiX7_LJ65mDI-OoUL6ofnz99v_66uv325eb66nZlpKjnlUHsLTVQQ99h37im7Vjb81paAT1lreKOW1ZzpupOOsldI5lqa-rAIkomxEV1c-S1Ee70lPxYZtYRvD4kYlprSGWZATWntlWsl8YB1Ip1SnFmTIONVVZ1TBWuD0euaduPaA2GOcHwiPRxJfiNXsedVqoW5YiF4O2JIMWf23IEPfpscBggYNxmzRuuGiXKWgUqj1BTTpATugcZRvXeMvreMnpvGX2yTOl78--MD133HimAj0eADy6mEX7FNFg9wzLE5BIE47MW_9f4C7bn1to</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2628683178</pqid></control><display><type>article</type><title>Apigenin exerts protective effect and restores ovarian function in dehydroepiandrosterone induced polycystic ovary syndrome rats: a biochemical and histological analysis</title><source>Taylor & Francis Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Peng, Fangxin ; Hu, Yichuan ; Peng, Shu ; Zeng, Ni ; Shi, Lei</creator><creatorcontrib>Peng, Fangxin ; Hu, Yichuan ; Peng, Shu ; Zeng, Ni ; Shi, Lei</creatorcontrib><description>Polycystic ovarian syndrome (PCOS) is one of the major causes encouraging the elevation of androgens, obesity along with menstrual complications. Here we study the effect of Apigenin in rat model of polycystic ovarian syndrome.
Female Sprague Dawley (SD) rats were treated with Dehydroepiandrosterone (DHEA) (6 mg/100g) opting the post-pubertal approach for developing rat model of polycystic ovarian syndrome, Metformin was used as standard. The treatments were given for 21 days along with coloproctological analysis. After the treatment regimen, the biochemical analysis was carried in plasma samples, whereas the ovaries were submitted for histopathological analysis.
The treatment of DHEA resulted in disturbed lipid profile and anti-oxidant status along with increased weight, ovarian diameter and cysts in rats confirming the development of PCOS. However, treatment of Apigenin showed ameliorative effect by improving the lipid profile and anti-oxidant status, the treatment also normalised the body weight, reduced ovarian diameter, cysts and restored the healthy follicles compared to control rats. The treatment of Apigenin also suppressed the levels of oestradiol and testosterone compared to control group, also, levels of progesterone were increased in Apigenin treated group of rats. The treatment of Apigenin suppressed the levels of inflammatory cytokines TNF-α and IL-6. It was observed that the effect of Apigenin were to some extent parallel to standard drug Metformin.
The findings confirmed that Apigenin ameliorates the disturbed hormonal levels, lipid profile and antioxidant status in PCOS rats.</description><identifier>ISSN: 0785-3890</identifier><identifier>EISSN: 1365-2060</identifier><identifier>DOI: 10.1080/07853890.2022.2034933</identifier><identifier>PMID: 35152800</identifier><language>eng</language><publisher>England: Taylor & Francis</publisher><subject>Animals ; anti-oxidant ; Apigenin ; Apigenin - adverse effects ; Dehydroepiandrosterone - adverse effects ; Disease Models, Animal ; Female ; Humans ; lipid profile ; polycystic ovarian syndrome ; Polycystic Ovary Syndrome - chemically induced ; Polycystic Ovary Syndrome - drug therapy ; Polycystic Ovary Syndrome - pathology ; Pregnancy, Childbirth & Women's Health ; Rats ; Rats, Sprague-Dawley</subject><ispartof>Annals of medicine (Helsinki), 2022-12, Vol.54 (1), p.578-587</ispartof><rights>2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group 2022</rights><rights>2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group 2022 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c534t-ceebd0ca4ab9eb6f67917b245d3ab01782f2d14218495f52f6518740fadee5133</citedby><cites>FETCH-LOGICAL-c534t-ceebd0ca4ab9eb6f67917b245d3ab01782f2d14218495f52f6518740fadee5133</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843206/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843206/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,27479,27901,27902,53766,53768,59116,59117</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35152800$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Peng, Fangxin</creatorcontrib><creatorcontrib>Hu, Yichuan</creatorcontrib><creatorcontrib>Peng, Shu</creatorcontrib><creatorcontrib>Zeng, Ni</creatorcontrib><creatorcontrib>Shi, Lei</creatorcontrib><title>Apigenin exerts protective effect and restores ovarian function in dehydroepiandrosterone induced polycystic ovary syndrome rats: a biochemical and histological analysis</title><title>Annals of medicine (Helsinki)</title><addtitle>Ann Med</addtitle><description>Polycystic ovarian syndrome (PCOS) is one of the major causes encouraging the elevation of androgens, obesity along with menstrual complications. Here we study the effect of Apigenin in rat model of polycystic ovarian syndrome.
Female Sprague Dawley (SD) rats were treated with Dehydroepiandrosterone (DHEA) (6 mg/100g) opting the post-pubertal approach for developing rat model of polycystic ovarian syndrome, Metformin was used as standard. The treatments were given for 21 days along with coloproctological analysis. After the treatment regimen, the biochemical analysis was carried in plasma samples, whereas the ovaries were submitted for histopathological analysis.
The treatment of DHEA resulted in disturbed lipid profile and anti-oxidant status along with increased weight, ovarian diameter and cysts in rats confirming the development of PCOS. However, treatment of Apigenin showed ameliorative effect by improving the lipid profile and anti-oxidant status, the treatment also normalised the body weight, reduced ovarian diameter, cysts and restored the healthy follicles compared to control rats. The treatment of Apigenin also suppressed the levels of oestradiol and testosterone compared to control group, also, levels of progesterone were increased in Apigenin treated group of rats. The treatment of Apigenin suppressed the levels of inflammatory cytokines TNF-α and IL-6. It was observed that the effect of Apigenin were to some extent parallel to standard drug Metformin.
The findings confirmed that Apigenin ameliorates the disturbed hormonal levels, lipid profile and antioxidant status in PCOS rats.</description><subject>Animals</subject><subject>anti-oxidant</subject><subject>Apigenin</subject><subject>Apigenin - adverse effects</subject><subject>Dehydroepiandrosterone - adverse effects</subject><subject>Disease Models, Animal</subject><subject>Female</subject><subject>Humans</subject><subject>lipid profile</subject><subject>polycystic ovarian syndrome</subject><subject>Polycystic Ovary Syndrome - chemically induced</subject><subject>Polycystic Ovary Syndrome - drug therapy</subject><subject>Polycystic Ovary Syndrome - pathology</subject><subject>Pregnancy, Childbirth & Women's Health</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><issn>0785-3890</issn><issn>1365-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>EIF</sourceid><sourceid>DOA</sourceid><recordid>eNp9Ustu1TAQjRCIlsIngLxkc4sfceKwQFQVj0qV2MDamtjje10ldrBzL-ST-Et8H63oho3HmjlzzozmVNVrRi8ZVfQdbZUUqqOXnHJeHlF3Qjypzplo5IrThj6tzveY1R50Vr3I-Y5SyltGn1dnQjLJFaXn1Z-rya8x-EDwN6Y5kynFGc3sd0jQufIjECxJmOdYHhJ3kDwE4rahgGIgpdPiZrEp4lQKJeYZUwxYKnZr0JIpDotZ8uzNoXshednDRiQJ5vyeAOl9NBscvYHhoLbxRW2I61MChiX7_LJ65mDI-OoUL6ofnz99v_66uv325eb66nZlpKjnlUHsLTVQQ99h37im7Vjb81paAT1lreKOW1ZzpupOOsldI5lqa-rAIkomxEV1c-S1Ee70lPxYZtYRvD4kYlprSGWZATWntlWsl8YB1Ip1SnFmTIONVVZ1TBWuD0euaduPaA2GOcHwiPRxJfiNXsedVqoW5YiF4O2JIMWf23IEPfpscBggYNxmzRuuGiXKWgUqj1BTTpATugcZRvXeMvreMnpvGX2yTOl78--MD133HimAj0eADy6mEX7FNFg9wzLE5BIE47MW_9f4C7bn1to</recordid><startdate>20221231</startdate><enddate>20221231</enddate><creator>Peng, Fangxin</creator><creator>Hu, Yichuan</creator><creator>Peng, Shu</creator><creator>Zeng, Ni</creator><creator>Shi, Lei</creator><general>Taylor & Francis</general><general>Taylor & Francis Group</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20221231</creationdate><title>Apigenin exerts protective effect and restores ovarian function in dehydroepiandrosterone induced polycystic ovary syndrome rats: a biochemical and histological analysis</title><author>Peng, Fangxin ; Hu, Yichuan ; Peng, Shu ; Zeng, Ni ; Shi, Lei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c534t-ceebd0ca4ab9eb6f67917b245d3ab01782f2d14218495f52f6518740fadee5133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Animals</topic><topic>anti-oxidant</topic><topic>Apigenin</topic><topic>Apigenin - adverse effects</topic><topic>Dehydroepiandrosterone - adverse effects</topic><topic>Disease Models, Animal</topic><topic>Female</topic><topic>Humans</topic><topic>lipid profile</topic><topic>polycystic ovarian syndrome</topic><topic>Polycystic Ovary Syndrome - chemically induced</topic><topic>Polycystic Ovary Syndrome - drug therapy</topic><topic>Polycystic Ovary Syndrome - pathology</topic><topic>Pregnancy, Childbirth & Women's Health</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Peng, Fangxin</creatorcontrib><creatorcontrib>Hu, Yichuan</creatorcontrib><creatorcontrib>Peng, Shu</creatorcontrib><creatorcontrib>Zeng, Ni</creatorcontrib><creatorcontrib>Shi, Lei</creatorcontrib><collection>Taylor & Francis Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Annals of medicine (Helsinki)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Peng, Fangxin</au><au>Hu, Yichuan</au><au>Peng, Shu</au><au>Zeng, Ni</au><au>Shi, Lei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Apigenin exerts protective effect and restores ovarian function in dehydroepiandrosterone induced polycystic ovary syndrome rats: a biochemical and histological analysis</atitle><jtitle>Annals of medicine (Helsinki)</jtitle><addtitle>Ann Med</addtitle><date>2022-12-31</date><risdate>2022</risdate><volume>54</volume><issue>1</issue><spage>578</spage><epage>587</epage><pages>578-587</pages><issn>0785-3890</issn><eissn>1365-2060</eissn><abstract>Polycystic ovarian syndrome (PCOS) is one of the major causes encouraging the elevation of androgens, obesity along with menstrual complications. Here we study the effect of Apigenin in rat model of polycystic ovarian syndrome.
Female Sprague Dawley (SD) rats were treated with Dehydroepiandrosterone (DHEA) (6 mg/100g) opting the post-pubertal approach for developing rat model of polycystic ovarian syndrome, Metformin was used as standard. The treatments were given for 21 days along with coloproctological analysis. After the treatment regimen, the biochemical analysis was carried in plasma samples, whereas the ovaries were submitted for histopathological analysis.
The treatment of DHEA resulted in disturbed lipid profile and anti-oxidant status along with increased weight, ovarian diameter and cysts in rats confirming the development of PCOS. However, treatment of Apigenin showed ameliorative effect by improving the lipid profile and anti-oxidant status, the treatment also normalised the body weight, reduced ovarian diameter, cysts and restored the healthy follicles compared to control rats. The treatment of Apigenin also suppressed the levels of oestradiol and testosterone compared to control group, also, levels of progesterone were increased in Apigenin treated group of rats. The treatment of Apigenin suppressed the levels of inflammatory cytokines TNF-α and IL-6. It was observed that the effect of Apigenin were to some extent parallel to standard drug Metformin.
The findings confirmed that Apigenin ameliorates the disturbed hormonal levels, lipid profile and antioxidant status in PCOS rats.</abstract><cop>England</cop><pub>Taylor & Francis</pub><pmid>35152800</pmid><doi>10.1080/07853890.2022.2034933</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0785-3890 |
| ispartof | Annals of medicine (Helsinki), 2022-12, Vol.54 (1), p.578-587 |
| issn | 0785-3890 1365-2060 |
| language | eng |
| recordid | cdi_crossref_primary_10_1080_07853890_2022_2034933 |
| source | Taylor & Francis Open Access; MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Animals anti-oxidant Apigenin Apigenin - adverse effects Dehydroepiandrosterone - adverse effects Disease Models, Animal Female Humans lipid profile polycystic ovarian syndrome Polycystic Ovary Syndrome - chemically induced Polycystic Ovary Syndrome - drug therapy Polycystic Ovary Syndrome - pathology Pregnancy, Childbirth & Women's Health Rats Rats, Sprague-Dawley |
| title | Apigenin exerts protective effect and restores ovarian function in dehydroepiandrosterone induced polycystic ovary syndrome rats: a biochemical and histological analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T18%3A37%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Apigenin%20exerts%20protective%20effect%20and%20restores%20ovarian%20function%20in%20dehydroepiandrosterone%20induced%20polycystic%20ovary%20syndrome%20rats:%20a%20biochemical%20and%20histological%20analysis&rft.jtitle=Annals%20of%20medicine%20(Helsinki)&rft.au=Peng,%20Fangxin&rft.date=2022-12-31&rft.volume=54&rft.issue=1&rft.spage=578&rft.epage=587&rft.pages=578-587&rft.issn=0785-3890&rft.eissn=1365-2060&rft_id=info:doi/10.1080/07853890.2022.2034933&rft_dat=%3Cproquest_cross%3E2628683178%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2628683178&rft_id=info:pmid/35152800&rft_doaj_id=oai_doaj_org_article_20d781b5cfaa48198821cc6e6d8d8918&rfr_iscdi=true |